Spero Therapeutics (SPRO) Total Liabilities (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Total Liabilities came in at $6.1 million in Q1 2026, down 86.13% YoY from $43.9 million in Q1 2025, and down 38.5% on a QoQ basis from $9.9 million in Q4 2025.
Spero Therapeutics (SPRO) Total Liabilities (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Total Liabilities data on file, last reported at $6.1 million in Q1 2026.
- Quarterly Total Liabilities fell 86.13% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (down 86.13% YoY) and the FY2025 annual result came in at $9.9 million, down 84.64% from the prior year.
- Total Liabilities slipped to $6.1 million in Q1 2026, from $9.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $83.4 million in Q1 2022 to a low of $6.1 million in Q1 2026.
- A 5-year average of $47.3 million and a median of $47.7 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 238.93% — and 2026, when it tumbled 86.13%.
- Tracing SPRO's Total Liabilities over 5 years: stood at $48.9 million in 2022, then jumped by 54.49% to $75.5 million in 2023, then dropped by 14.67% to $64.4 million in 2024, then plunged by 84.64% to $9.9 million in 2025, then sank by 38.5% to $6.1 million in 2026.
- The last three Total Liabilities figures came in at $6.1 million (Q1 2026), $9.9 million (Q4 2025), and $27.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | 8.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.56 Mn |
| Mar 31, 2026 | 6.09 Mn |
| Dec 31, 2025 | 9.90 Mn |
| Sep 30, 2025 | 27.68 Mn |
| Jun 30, 2025 | 29.29 Mn |
| Mar 31, 2025 | 43.90 Mn |
| Dec 31, 2024 | 64.42 Mn |
| Sep 30, 2024 | 69.65 Mn |
| Jun 30, 2024 | 69.38 Mn |
| Mar 31, 2024 | 71.45 Mn |
| Dec 31, 2023 | 75.50 Mn |
| Sep 30, 2023 | 53.40 Mn |
| Jun 30, 2023 | 44.10 Mn |
| Mar 31, 2023 | 47.71 Mn |
| Dec 31, 2022 | 48.87 Mn |
| Sep 30, 2022 | 31.99 Mn |
| Jun 30, 2022 | 27.71 Mn |
| Mar 31, 2022 | 83.36 Mn |
| Dec 31, 2021 | 82.78 Mn |
| Sep 30, 2021 | 32.80 Mn |